Status:
UNKNOWN
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Brief Summary
This is a multicenter, observational, single-arm real world study to evaluate the efficacy and safety of pyrotinib after lapatinib progression.
Detailed Description
HER2-positive breast cancers account for 15%-20% of all breast cancers. The development of HER2 targeted therapies have greatly improved the survival of HER2-positive breast cancer patients. Lapatinib...
Eligibility Criteria
Inclusion
- Female and 18-70 years old
- Metastatic or locally recurrent HER2-positive breast cancer
- Patients received pyrotinib-based therapy after lapatinib failure in treatment for metastasis
- Complete and accurate medical data
Exclusion
- \- Incomplete medical data
Key Trial Info
Start Date :
August 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04899128
Start Date
August 1 2018
End Date
June 1 2021
Last Update
May 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China